CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock
(NasdaqGM:CAMP), CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) — CAMP4 Therapeutics Corporation (“CAMP4” or the “Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the pricing of […]